Serum and lower respiratory tract tobramycin concentrations produced by inhaled tobramycin (TOBI) in young children with cystic fibrosis

Pediatric Pulmonology

Volumn 28, Issue SUPPL. 19, 1999, Pages 106-108

  Rosenfeld, Margaret ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347761601     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Wagener JS, Kahn TZ, Copenhaver SC, Accurso FJ. Early inflammation and the development of pulmonary disease in cystic fibrosis. Pediatric Pulmonology 1997; 16:267-8.
2. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutierrez JP, Hull J, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 1156:1197-204.
3. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 328:1740-1746.
4. Ramsey BW, Pep MS, Quan JM, et.al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. New Eng J Med 1999; 340:23-30.
5. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60:532-538.